Foundation Medicine, ARIAD announce collaboration to study AP26113

theflyonthewall.com

Foundation Medicine and ARIAD announced a genomic profiling collaboration to study AP26113, ARIAD's investigational dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer and other cancers. Foundation Medicine will work with ARIAD to generate genomic profile information for patients enrolled in ARIAD's ongoing Phase 1/2 trial and these data will be matched with clinical observations to understand the activity and selectivity profile of AP26113.

Rates

View Comments (0)